PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy
Petros Grivas, Vadim S. Koshkin, Xiangying Chu, Suzanne Cole, Rohit Jain, Robert Dreicer, Jeremy Cetnar, Debasish Sundi, Benjamin A. Gartrell, Matthew D. Galsky, Brianna Woo, Elsa M. Li-Ning-Tapia, Noah M. Hahn, Michael A. Carducci
Topics & Concepts
MedicineCohortBladder cancerCystectomyOncologyCisplatinCommon Terminology Criteria for Adverse EventsNivolumabInternal medicineAdverse effectNeoadjuvant therapyUrologyCancerChemotherapyImmunotherapyBreast cancerBladder and Urothelial Cancer TreatmentsEsophageal Cancer Research and TreatmentTissue Engineering and Regenerative Medicine